golin
c
earp
j
tien
h
stewart
p
porter
c
howi
l
random
control
trial
motiv
interviewingbas
intervent
improv
adher
antiretrovir
therapi
art
among
patient
fail
initi
art
j
acq
immun
defi
surviv
benefi
patient
acut
respiratori
distress
syndrom
ard
due
extracorpor
membran
oxygen
ecmo
treatment
invit
consider
whether
ecmo
might
provid
import
medic
countermeasur
ard
result
natur
hazard
act
terror
anthrax
spore
bioengin
nativ
avian
fl
u
strain
chemic
agent
chlorin
ga
deriv
lead
lung
injuri
result
ard
framework
need
ecmo
incorpor
comprehens
emerg
prepared
programm
ecmo
provid
continu
circulatori
support
oxygen
patient
cardiac
failur
pulmonari
failur
alreadi
establish
treatment
heart
failur
cardiac
surgeri
becom
increasingli
accept
treatment
adult
lung
injuri
oxygen
convent
mean
technolog
advanc
facilit
implement
ecmo
critic
care
improv
outcom
patient
ard
improv
technolog
combin
increas
confi
denc
use
ecmo
share
experi
report
intern
meet
registri
extracorpor
life
support
organ
elso
led
substanti
increas
use
fi
gure
analysi
us
nationwid
inpati
sampl
ni
databas
show
past
decad
ecmo
support
heart
surgeri
postcardiotomi
respiratori
failur
increas
six
time
sever
acut
respiratori
syndrom
sar
fl
u
epidem
show
need
lifesav
technolog
abil
ecmo
potenti
address
need
treatment
ard
success
applic
outbreak
rate
ecmo
use
respiratori
failur
rapidli
increas
portabl
ecmo
devic
avail
allow
ecmo
initi
outsid
hospit
set
french
german
taiwanes
centr
report
feasibl
use
ecmo
cardiopulmonari
arrest
train
interdisciplinari
team
french
fi
eld
ecmo
programm
establish
specifi
calli
deal
anticip
need
mobil
ecmo
epidem
programm
enhanc
possibl
incorpor
ecmo
comprehens
emerg
prepared
programm
medic
michael
donnesci
photo
librari
countermeasur
epidem
terrorist
action
could
lead
ard
howev
evid
use
type
set
limit
although
clinic
inform
case
seri
trial
elso
registri
provid
data
similar
devic
disast
prepared
regimen
devic
fulli
test
disast
situat
aris
bleed
embol
infecti
complic
inher
use
ecmo
might
increas
use
mass
casualti
set
inexperienc
hand
indic
use
ecmo
could
inadvert
erron
expand
includ
healthier
patient
view
present
enthusiasm
technolog
success
treat
patient
sar
furthermor
ecmo
might
discontinu
futil
case
wherebi
use
lead
needless
prolong
patient
discomfort
inappropri
use
scare
resourc
factor
make
regulatori
approv
consider
ecmo
medic
countermeasur
challeng
howev
approv
need
allow
product
dissemin
suffi
cient
devic
use
publichealth
emerg
regulatori
perspect
develop
ecmo
medic
countermeasur
need
follow
diff
erent
pathway
usual
process
invit
even
radic
chang
innov
pathway
use
us
food
drug
administr
type
number
patient
aff
ect
act
bioterror
publichealth
emerg
ecmo
could
treat
unknown
devic
fulli
test
situat
occur
present
approv
devic
includ
ecmo
approach
use
base
present
clinic
evid
model
expert
opinion
novel
devic
potenti
medic
countermeasur
diff
erent
type
threshold
evid
need
acceler
approv
appropri
system
assess
need
develop
incorpor
new
concept
use
accumul
data
surrog
evid
eff
ectiv
safeti
medic
countermeasur
set
allow
ecmo
includ
strategi
prepared
without
delay
amount
type
evid
vari
depend
whether
devic
use
pose
high
clinic
risk
eg
ecmo
low
clinic
risk
eg
novel
type
wound
dress
import
consider
regulatori
bodi
approv
devic
publichealth
emerg
defi
ning
indic
use
prohibit
inappropri
futil
care
infrastructur
need
develop
decis
support
system
use
devic
healthcar
profession
develop
simul
use
public
health
emerg
regulatori
bodi
formul
new
polici
ensur
eff
ectiv
medic
care
provid
ethic
concern
healthcar
profession
patient
famili
address
formal
defi
nition
circumst
devic
use
would
reduc
burden
physician
decid
devic
appropri
use
futil
government
profession
agenc
worldwid
collabor
build
framework
appropri
use
ecmo
publichealth
emerg
framework
would
need
includ
evid
need
regulatori
approv
variou
clinic
ethic
fi
nancial
aspect
ecmo
avail
use
combin
global
experi
implement
ecmo
infl
uenza
epidem
done
alreadi
mani
countri
could
fi
rst
phase
framework
addit
framework
develop
new
system
data
collect
plan
incorpor
new
technolog
ecmo
imper
guidanc
polici
debat
could
lead
measur
thought
use
technolog
disast
occur
trial
kafk
leav
reader
last
impress
engag
untouch
impos
bureaucrat
process
protagonist
struggl
make
sens
complex
machineri
forc
beyond
control
hinder
daili
life
although
fi
ctional
trial
tribul
repres
extrem
today
respiratori
medic
research
similarli
fi
nd
unabl
move
forward
translat
research
mani
instanc
rule
beyond
control
sentiment
promin
european
respiratori
societi
presidenti
summit
break
barrier
lung
health
better
environ
better
medicin
held
rome
juli
meet
took
place
auspic
italian
presid
council
european
union
identifi
ed
respiratori
diseas
prioriti
today
exig
rule
even
aspirin
corticosteroid
would
adher
standard
regulatori
system
enorm
attrit
one
approv
drug
start
molecul
process
take
around
year
drug
discoveri
regulatori
approv
unsurprisingli
respiratori
medicin
nine
new
class
therapi
past
year
respiratori
medicin
lowest
success
rate
therapeut
area
bring
new
drug
market
drug
enter
clinic
trial
gain
approv
overli
complex
regulatori
environ
exagger
concern
safeti
power
disincent
peopl
might
otherwis
becom
involv
drug
research
develop
new
drug
cost
billion
dollar
compli
high
expect
clear
mechanist
proof
concept
defi
ned
effi
caci
endpoint
term
respiratori
drug
develop
specifi
c
challeng
need
overcom
name
incomplet
understand
pathophysiolog
diseas
need
better
understand
surrog
endpoint
make
proof
concept
diffi
cult
novel
innov
compound
littl
doubt
insist
fev
primari
endpoint
treatment
obstruct
airway
diseas
hamper
develop
new
drug
much
research
focus
endpoint
detriment
potenti
endpoint
analysi
respiratori
drug
discoveri
present
european
medicin
agenc
ema
rome
summit
show
eight
innov
medicin
licens
ema
refer
respiratori
drug
exclud
cancer
antiinfect
drug
explan
found
within
framework
govern
clinic
trial
europ
european
commiss
report
